RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 517.09 Thousand CAD | -70.39% |
| 2022 | 1.74 Million CAD | -34.15% |
| 2021 | 2.65 Million CAD | 57.68% |
| 2020 | 1.68 Million CAD | -48.73% |
| 2019 | 3.28 Million CAD | 14.69% |
| 2018 | 2.86 Million CAD | -52.26% |
| 2017 | 5.99 Million CAD | 39.75% |
| 2016 | 4.28 Million CAD | -15.04% |
| 2015 | 5.04 Million CAD | -3.14% |
| 2014 | 5.21 Million CAD | 39.43% |
| 2013 | 3.73 Million CAD | -16.47% |
| 2012 | 4.47 Million CAD | 19.84% |
| 2011 | 3.73 Million CAD | 83.34% |
| 2010 | 2.03 Million CAD | 1360.33% |
| 2009 | 139.44 Thousand CAD | 3.13% |
| 2008 | 135.21 Thousand CAD | -63.57% |
| 2007 | 371.13 Thousand CAD | -24.46% |
| 2006 | 491.31 Thousand CAD | 63.81% |
| 2005 | 299.92 Thousand CAD | -42.21% |
| 2004 | 518.98 Thousand CAD | 452.35% |
| 2003 | 93.96 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 214.52 Thousand CAD | -45.1% |
| 2024 Q2 | 249.32 Thousand CAD | 16.22% |
| 2023 Q3 | 413.91 Thousand CAD | 44.85% |
| 2023 Q1 | 551.06 Thousand CAD | 16.75% |
| 2023 FY | 1.73 Million CAD | -0.45% |
| 2023 Q2 | 285.74 Thousand CAD | -48.15% |
| 2023 Q4 | 390.74 Thousand CAD | -5.6% |
| 2022 Q2 | 562.96 Thousand CAD | 28.26% |
| 2022 FY | 1.74 Million CAD | -34.15% |
| 2022 Q1 | 438.9 Thousand CAD | -21.58% |
| 2022 Q4 | 471.98 Thousand CAD | 73.16% |
| 2022 Q3 | 272.57 Thousand CAD | -51.58% |
| 2021 Q1 | 568.29 Thousand CAD | 71.24% |
| 2021 Q3 | 634.25 Thousand CAD | -28.74% |
| 2021 Q4 | 559.66 Thousand CAD | -11.76% |
| 2021 Q2 | 890 Thousand CAD | 56.61% |
| 2021 FY | 2.65 Million CAD | 57.68% |
| 2020 Q4 | 331.87 Thousand CAD | -45.54% |
| 2020 Q2 | 338.6 Thousand CAD | -14.72% |
| 2020 Q1 | 397.05 Thousand CAD | -39.91% |
| 2020 FY | 1.68 Million CAD | -48.73% |
| 2020 Q3 | 609.4 Thousand CAD | 79.98% |
| 2019 Q3 | 624.74 Thousand CAD | -37.31% |
| 2019 Q2 | 996.63 Thousand CAD | 0.84% |
| 2019 FY | 3.28 Million CAD | 14.69% |
| 2019 Q4 | 660.73 Thousand CAD | 5.76% |
| 2019 Q1 | 988.35 Thousand CAD | -2.71% |
| 2018 FY | 2.86 Million CAD | -52.26% |
| 2018 Q2 | 590.34 Thousand CAD | 21.39% |
| 2018 Q1 | 486.32 Thousand CAD | -16.88% |
| 2018 Q4 | 1.01 Million CAD | 32.3% |
| 2018 Q3 | 767.87 Thousand CAD | 30.07% |
| 2017 Q4 | 585.1 Thousand CAD | -51.82% |
| 2017 Q3 | 1.21 Million CAD | -51.28% |
| 2017 Q2 | 2.49 Million CAD | 46.68% |
| 2017 Q1 | 1.69 Million CAD | -3.86% |
| 2017 FY | 5.99 Million CAD | 39.75% |
| 2016 Q2 | 786.62 Thousand CAD | -28.13% |
| 2016 Q4 | 1.76 Million CAD | 176.66% |
| 2016 FY | 4.28 Million CAD | -15.04% |
| 2016 Q1 | 1.09 Million CAD | -15.73% |
| 2016 Q3 | 638.92 Thousand CAD | -18.78% |
| 2015 FY | 5.04 Million CAD | -3.14% |
| 2015 Q4 | 1.29 Million CAD | 10.22% |
| 2015 Q3 | 1.17 Million CAD | -13.74% |
| 2015 Q2 | 1.36 Million CAD | 13.47% |
| 2015 Q1 | 1.2 Million CAD | -13.45% |
| 2014 Q2 | 1.37 Million CAD | 16.16% |
| 2014 Q3 | 1.26 Million CAD | -8.17% |
| 2014 Q1 | 1.18 Million CAD | 3.51% |
| 2014 FY | 5.21 Million CAD | 39.43% |
| 2014 Q4 | 1.39 Million CAD | 10.21% |
| 2013 FY | 3.73 Million CAD | -16.47% |
| 2013 Q4 | 1.14 Million CAD | 28.86% |
| 2013 Q2 | 1.01 Million CAD | 45.1% |
| 2013 Q3 | 887.01 Thousand CAD | -12.23% |
| 2013 Q1 | 696.49 Thousand CAD | -25.14% |
| 2012 Q1 | 723.33 Thousand CAD | -47.23% |
| 2012 Q2 | 1.74 Million CAD | 140.7% |
| 2012 Q4 | 930.34 Thousand CAD | 12.55% |
| 2012 Q3 | 826.6 Thousand CAD | -52.52% |
| 2012 FY | 4.47 Million CAD | 19.84% |
| 2011 Q3 | 696.39 Thousand CAD | -28.25% |
| 2011 Q1 | 713.62 Thousand CAD | -62.98% |
| 2011 Q2 | 970.58 Thousand CAD | 36.01% |
| 2011 Q4 | 1.37 Million CAD | 96.83% |
| 2011 FY | 3.73 Million CAD | 83.34% |
| 2010 Q3 | 54.81 Thousand CAD | 43.79% |
| 2010 Q2 | 38.12 Thousand CAD | 139.21% |
| 2010 Q1 | 15.93 Thousand CAD | -59.19% |
| 2010 Q4 | 1.92 Million CAD | 3416.37% |
| 2010 FY | 2.03 Million CAD | 1360.33% |
| 2009 Q3 | 17.41 Thousand CAD | -56.39% |
| 2009 Q4 | 39.05 Thousand CAD | 124.19% |
| 2009 Q2 | 39.94 Thousand CAD | -7.19% |
| 2009 Q1 | 43.03 Thousand CAD | 31.02% |
| 2009 FY | 139.44 Thousand CAD | 3.13% |
| 2008 Q1 | 39.04 Thousand CAD | 34.14% |
| 2008 Q4 | 32.84 Thousand CAD | -14.46% |
| 2008 Q3 | 38.39 Thousand CAD | 51.72% |
| 2008 Q2 | 25.3 Thousand CAD | -35.19% |
| 2008 FY | 135.21 Thousand CAD | -63.57% |
| 2007 Q3 | 133.25 Thousand CAD | 80.9% |
| 2007 Q1 | 135.59 Thousand CAD | -50.14% |
| 2007 FY | 371.13 Thousand CAD | -24.46% |
| 2007 Q4 | 29.11 Thousand CAD | -78.15% |
| 2007 Q2 | 73.65 Thousand CAD | -45.68% |
| 2006 Q3 | 90.84 Thousand CAD | -3.94% |
| 2006 Q1 | 33.89 Thousand CAD | 48.54% |
| 2006 FY | 491.31 Thousand CAD | 63.81% |
| 2006 Q4 | 271.96 Thousand CAD | 199.36% |
| 2006 Q2 | 94.57 Thousand CAD | 179.03% |
| 2005 Q3 | 74.46 Thousand CAD | -11.68% |
| 2005 FY | 299.92 Thousand CAD | -42.21% |
| 2005 Q2 | 84.3 Thousand CAD | -28.56% |
| 2005 Q1 | 118 Thousand CAD | 314.92% |
| 2005 Q4 | 22.81 Thousand CAD | -69.35% |
| 2004 Q1 | 19.27 Thousand CAD | 0.0% |
| 2004 Q2 | 130.57 Thousand CAD | 577.48% |
| 2004 Q4 | 28.44 Thousand CAD | -90.59% |
| 2004 FY | 518.98 Thousand CAD | 452.35% |
| 2004 Q3 | 302.16 Thousand CAD | 131.42% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | 93.96 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 61.279% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.612% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -32.736% |
| Nascent Biotech, Inc. | 2.22 Million USD | 76.811% |
| Qrons Inc. | 643.67 Thousand USD | 19.665% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 44.008% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 98.25% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.749% |
| Skye Bioscience, Inc. | 13.54 Million USD | 96.183% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -24.458% |
| Rebus Holdings, Inc. | 664 Thousand USD | 22.124% |
| CSL Limited | 3.44 Billion USD | 99.985% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.1% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 95.242% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 96.77% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 89.744% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.404% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 89.485% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -97.572% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.396% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 82.268% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 65.571% |
| Mesoblast Limited | 5.9 Million USD | 91.239% |
| Marizyme, Inc. | 19.23 Million USD | 97.312% |
| Genus plc | 147.7 Million USD | 99.65% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 94.11% |
| Pharming Group N.V. | 225.49 Million USD | 99.771% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 74.76% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 61.455% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 93.799% |
| ContraFect Corporation | 56.88 Million USD | 99.091% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 88.271% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 65.032% |
| IMV Inc. | 37.7 Million USD | 98.629% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 81.468% |
| MultiCell Technologies, Inc. | 567.42 USD | -91031.085% |
| ONE Bio Corp. | 6.44 Million USD | 91.975% |
| Accustem Sciences Inc. | 3.74 Million USD | 86.198% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.398% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 2.795% |
| Q BioMed Inc. | 3.43 Million USD | 84.953% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.908% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 80.32% |
| Biomind Labs Inc. | 994.18 Thousand USD | 47.988% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.479% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 70.614% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 92.303% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 72.264% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2168.384% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 71.822% |
| GB Sciences, Inc. | 1.42 Million USD | 63.598% |
| Alpha Cognition Inc. | 9.7 Million USD | 94.672% |
| HST Global, Inc. | 140.9 Thousand USD | -266.977% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 54.032% |
| Halberd Corporation | 74.84 Thousand USD | -590.917% |
| Enzolytics Inc. | 2.17 Million USD | 76.275% |
| Agentix Corp. | 1.37 Million USD | 62.304% |
| Resverlogix Corp. | 12.71 Million USD | 95.932% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 85.836% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.966% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 50.47% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 78.499% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 67.259% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 84.814% |
| AVAX Technologies, Inc. | 7.31 Million USD | 92.926% |
| Zenith Capital Corp. | 8.94 Million USD | 94.218% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.937% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2868.234% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 78.94% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -201.498% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 73.081% |
| Kadimastem Ltd | 2.41 Million USD | 78.545% |
| Helix BioMedix, Inc. | 1.97 Million USD | 73.779% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -184.925% |
| LadRx Corporation | 3.81 Million USD | 86.434% |
| Cell Source, Inc. | 4.32 Million USD | 88.045% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 44.008% |
| NovAccess Global Inc. | 2.46 Million USD | 79.037% |
| Affymax, Inc. | 39.38 Million USD | 98.687% |
| Itoco Inc. | 919.14 Thousand USD | 43.742% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 87.8% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 53.789% |
| Mobile Lads Corp. | 554.54 Thousand USD | 6.753% |
| CytoDyn Inc. | 18.05 Million USD | 97.136% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1954.496% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -134.96% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 63.579% |
| SYBLEU INC | 160.87 Thousand USD | -221.425% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 71.531% |
| International Stem Cell Corporation | 5.27 Million USD | 90.19% |
| Bioxytran, Inc. | 3.82 Million USD | 86.464% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -882.288% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -2441.887% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.574% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 68.041% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 29.727% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 83.378% |
| Neutra Corp. | 243.82 Thousand USD | -112.08% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 97.038% |
| PureTech Health plc | 144.59 Million USD | 99.642% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 97.476% |
| IXICO plc | 4.7 Million USD | 89.014% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 94.122% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.561% |
| CSL Limited | 3.89 Billion USD | 99.987% |
| Cellectis S.A. | 97.32 Million USD | 99.469% |